Rare Metabolics Life-Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.09 Cr
- Satisfied Charges ₹ 1.07 Cr
- Revenue Growth 77.56%
- Profit Growth 327.22%
- Ebitda 57.84%
- Net Worth 46.55%
- Total Assets 132.21%
About Rare Metabolics Life-Sciences
Rare Metabolics Life-Sciences Private Limited (RMLPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 May 2015 (Nine years and eight months 14 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.09 Cr. The company has closed loans amounting to ₹1.07 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kripa Shanker and Shobha Data serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100DL2015PTC280629
-
Company No.
280629
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 May 2015
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Rare Metabolics Life-Sciences Private Limited offer?
Rare Metabolics Life-Sciences Private Limited offers a wide range of products and services, including Metallurgical & Lab Microscopes, Digital Microscope, Anti Cancer Medicines, Oncology Drug, Cardiovascular Drugs & Medication, Immunosuppressive Drugs, Microscope.
Who are the key members and board of directors at Rare Metabolics Life-Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kripa Shanker
|
Director | 22-May-2015 | Current |
|
Shobha Data
|
Director | 22-May-2015 | Current |
Financial Performance of Rare Metabolics Life-Sciences.
Rare Metabolics Life-Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 77.56% increase. The company also saw a substantial improvement in profitability, with a 327.22% increase in profit. The company's net worth Soared by an impressive increase of 46.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rare Metabolics Life-Sciences?
In 2023, Rare Metabolics Life-Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Pegasys Life Sciences Private LimitedKripa Shanker is a mutual person
-
Think Big E-Ventures Private Limited
Kripa Shanker is a mutual person
Charges (Loans)
₹10.88 M
₹10.68 M
Charges Breakdown by Lending Institutions
- Others : 1.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Nov 2022 | Others | ₹1.09 Cr | Open |
| 04 Nov 2019 | Yes Bank Limited | ₹1.07 Cr | Satisfied |
How Many Employees Work at Rare Metabolics Life-Sciences?
Unlock and access historical data on people associated with Rare Metabolics Life-Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rare Metabolics Life-Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rare Metabolics Life-Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
